Технологии получения тераностических пар радиофармацевтических лекарственных препаратов для диагностики и лечения рака предстательной железы: обзор литературы

В настоящее время рак предстательной железы (РПЖ) — одно из наиболее распространенных злокачественных новообразований у мужчин. Ежегодно в мире выявляется свыше 400 000 случаев рака предстательной железы; в ряде стран он занимает в структуре онкологических заболеваний второе или третье место. Перспективной технологией диагностики и лечения онкологических заболеваний в ядерной медицине является радиотераностика — комплексный подход, сочетающий в себе диагностику и терапию с помощью одной химической молекулы, но различных радиоизотопов. Для РПЖ используют диагностический радиоизотоп ⁶⁸Ga и терапевтические изотопы — ¹⁷⁷Lu и ²²⁵Ac. В статье рассматриваются современные технологии получения радиофармацевтических препаратов для диагностики и радионуклидной терапии РПЖ с помощью тераностических пар на основе изотопов ⁶⁸Gа/¹⁷⁷Lu, а также перспективы синтеза новых терапевтических радиофармацевтических лекарственных препаратов, меченных изотопом ¹⁷⁷Lu.

1. Ларенков А.А. Получение препаратов 68Ga высокой химической и радиохимической чистоты для позитронно-эмиссионной томографии: дис. … канд. хим. наук: 02.00.14. ФГБУ ГНЦ ФМБЦ им. А. И. Бурназяна ФМБА России, Москва, 2015. 154 с.].

2. Velikyan I, Beyer GJ, Långström B. Microwavesupported preparation of 68Ga bioconjugates with high specific radioactivity. Bioconjug Chem. 2004;15(3)554– 60. DOI: 10.1021/bc030078f.

3. Zhernosekov KP, Filosofov DV, Baum RP et al. Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007;48(10):1741–8. DOI: 10.2967/jnumed.107.040378.

4. Asti M, De Pietri G, Fraternali A, et al. Validation of 68Ge/68Ga generator processing by chemical purification for routine clinical application of 68GaDOTATOC. Nucl Med Biol. 2008;35(6):721–4. DOI: 10.1016/j.nucmedbio.2008.04.006.

5. Ocak M, Antretter M, Knopp R, et al. Full automation of 68Ga labelling of DOTA-peptides including cation exchange prepurification. Appl Radiat Isot. 2010;68(2):297–302. DOI: 10.1016/j.apradiso.2009.10.006.

6. Belosi F, Cicoria G, Lodi F, et al. Generator breakthrough and radionuclidic purification in automated synthesis of 68Ga-DOTANOC. Curr Radiopharm. 2013;6(2):72–7. DOI: 10.2174/1874471011306020002.

7. Schultz MK, Mueller D, Baum RP, et al. A new automated NaCl based robust method for routine production of gallium-68 labeled peptides. Applied Radiation and Isotopes. 2013;76:46–54. https://doi.org/10.1016/j.apradiso.2012.08.011.

8. Schuhmacher J, Maier-Borst W. A new 68Ge/68Ga radioisotope generator system for production of 68Ga in dilute HCl. The International Journal of Applied Radiation and Isotopes. 1981;32(1):31–36. DOI:10.1016/0020708x(81)90174-5.

9. Meyer GJ, Mäcke H, Schuhmacher J, et al. 68Galabelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging. 2004; 31(8):1097–104. DOI: 10.1007/s00259-004-1486-0.

10. de Blois E, Sze Chan H, Naidoo C et al. Characteristics of SnO2-based 68Ge/68Ga generator and aspects of radiolabelling DOTA-peptides. Appl Radiat Isot. 2011;69(2):308–15. DOI: 10.1016/j.apradiso.2010.11.015.

11. Mueller D, Klette I, Baum RP. Purification and labeling strategies for 68Ga from 68Ge/ 68Ga generator eluate. Recent Results Cancer Res. 2013;194:77–87. DOI: 10.1007/978-3-642-27994-2_5.

12. Антуганов Д.О., Рыжкова Д.В., Тимофеев В.В. и др. Модификация анионообменной методики концентрирования изотопа 68Ga и автоматический синтез радиофармпрепарата [68Ga] Ga-ПСМА-11. Радиохимия. 2019;61(6):523–528].

13. Israeli RS, Powell CT, Fair WR, et al. Molecular cloning of a complementary DNA encoding a prostatespecific membrane antigen. Cancer Res. 1993;53(2):227–30.

14. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528–39. DOI: 10.1002/jcb.10661.

15. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9(17):6357–62.

16. Eder M, Schäfer M, Bauder-Wüst U, et al. 68Gacomplex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23(4):688–97. DOI: 10.1021/bc200279b.

17. Afshar-Oromieh A, Haberkorn U, Eder M, et al. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39(6):1085–6. DOI: 10.1007/s00259-012-2069-0.

18. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486–95. DOI: 10.1007/s00259012-2298-2.

19. Ajish Kumar KS, Mathur A. Total chemical synthesis of PSMA-11: API for 68Ga-PSMA-11 used for prostate cancer diagnosis. European Journal of Medicinal Chemistry Reports. 2021; 3:100014. https://doi.org/10.1016/j.ejmcr.2021.100014.

20. Benešová M, Schäfer M, Bauder-Wüst U, et al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J Nucl Med. 2015;56(6):914–20. DOI: 10.2967/jnumed.114.147413.

21. Benešová M, Bauder-Wüst U, Schäfer M, et al. Linker Modification Strategies To Control the ProstateSpecific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. J Med Chem. 2016;59(5):1761–75. DOI: 10.1021/acs.jmedchem.5b01210.

22. on Eyben FE, Picchio M, von Eyben R, et al. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2018;4(5):686–693. DOI: 10.1016/j.euf.2016.11.002.

23. Baratto L, Jadvar H, Iagaru A. Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors. Mol Imaging Biol. 2018; 20(4):501–509. DOI: 10.1007/s11307-017-1151-1.

24. Minamimoto R, Sonni I, Hancock S, et al. Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging. J Nucl Med. 2018;59(5):803–808. DOI: 10.2967/jnumed.117.197624.

25. Minamimoto R, Hancock S, Schneider B, et al. Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2016;57(4):557–62. DOI: 10.2967/jnumed.115.168393.

26. Eder M, Schäfer M, Bauder-Wüst U, et al. Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate. 2014;74(6):659–68. DOI: 10.1002/pros.22784.

27. Bandari RP, Jiang Z, Reynolds TS, et al. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14) NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer. Nucl Med Biol. 2014;41(4):355–63. DOI: 10.1016/j.biopha.2016.12.083.

28. Escudero-Castellanos A, Ocampo-García B, Ferro-Flores G, et al. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer. Nucl Med Commun. 2019;40(3):278– 286. DOI: 10.1097/MNM.0000000000000966.

29. Liolios C, Schäfer M, Haberkorn U, et al. Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer. Bioconjug Chem. 2016;27(3):737–51. DOI: 10.1021/acs.bioconjchem.5b00687.

30. Mendoza-Figueroa MJ, Escudero-Castellanos A, Ramirez-Nava GJ, et al. Preparation and preclinical evaluation of 68Ga-iPSMA-BN as a potential heterodimeric radiotracer for PET-imaging of prostate cancer. J. Radioanal. Nucl. Chem. 2018;318:2097–2105. DOI: 10.1007/s10967-018-6285-3.

31. Casanueva FF, Perez FR, Casabiell X, et al. Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines. Proc. Natl. Acad. Sci. USA. 1996;93:1406–1411. DOI: 10.1073/pnas.93.4.1406.

32. Mansi R, Fleischmann A, Mäcke HR, et al. Targeting GRPR in urological cancers — from basic research to clinical application. Nat. Rev. Urol. 2013;10:235–244. DOI: 10.1038/nrurol.2013.42.

33. Abouzayed A, Yim C-B, Mitran B, et al. Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/ PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer. Pharmaceutics. 2019;11:358. DOI: 10.3390/pharmaceutics11070358.

34. Mitran B, Varasteh Z, Abouzayed A, et al. Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer. Cancers (Basel). 2019;11(9):1371. DOI: 10.3390/cancers11091371

35. Lundmark F, Abouzayed A, Mitran B, et al. Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model. Pharmaceutics. 2020;12(7):614. DOI: 10.3390/pharmaceutics12070614.

36. Lundmark F, Abouzayed A, Rinne SS, et al. Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [68Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation. Cancers (Basel). 2023;15(2):442. DOI: 10.3390/cancers15020442.

37. Qaim SM. Theranostic radionuclides: recent advances in production methodologies. J Radioanal Nucl Chem. 2019;322:1257–1266. DOI: 10.1007/s10967-01906797-y.

38. Velikyan I, Maecke H, Langstrom B. Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjug Chem. 2008;19(2):569–73. DOI: 10.1021/bc700341x.

39. André JP, Maecke HR, Zehnder M, et al. 1,4,7-Triazacyclononane-1-succinic acid-4,7-diacetic acid (NODASA): a new bifunctional chelator for radio galliumlabelling of biomolecules. Chemical Communications. 1998;12:1301–1302. DOI: 10.1039/a801294f.

40. Viola NA, Rarig RS, Ouellette W, et al. Synthesis, structure and thermal analysis of the gallium complex of 1,4,7,10-tetraazacyclo-dodecane-N,N’,N’’,N’’’-tetraacetic acid (DOTA). Polyhedron. 2006;25(18):3457–3462. https:// doi.org/10.1016/j.poly.2006.06.039.

41. Clarke ET, Martell AE. Stabilities of the Fe(III), Ga(III) and In(III) chelates of N,N’,N’’-triazacyclononanetriacetic acid.Inorganica Chimica Acta. 1991;181:273– 280. DOI: 10.1016/S0020-1693(00)86821-8.

42. Ajish Kumar KS, Mathur A. A convenient total synthesis of PSMA-617: A prostate specific membrane antigen (PSMA) ligand for prostate cancer endotherapeutic applications. European Journal of Medicinal Chemistry Reports. 2022;6:100084. https:// doi.org/10.1016/j.ejmcr.2022.100084.

43. Pandey U, Gamre N, Lohar SP, et al. A systematic study on the utility of CHX-A’’-DTPA-NCS and NOTA-NCS as bifunctional chelators for 177Lu radiopharmaceuticals. Appl Radiat Isot. 2017;127:1–6. DOI: 10.1016/j.apradiso.2017.04.028

44. Ahenkorah S, Murce E, Cawthorne C et al. 3p-CNETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals. Theranostics. 2022;12(13):5971–5985. DOI: 10.7150/thno.75336.

45. Zhuo L, Yang X, Liao W, et al. Comparative cell uptake study of FITC-/177Lu-labeled RM26 monomer, dimer and trimer on PC-3: improving binding affinity of gastrin releasing peptide receptor (GRPR) antagonist via bivalency/trivalency. Journal of Radioanalytical and Nuclear Chemistry. 2019;319:881–889. DOI: 10.1007/s10967-018-6396-x.